AKT1 and neoplasm: MK-2206, a small-molecule AKT pathway inhibitor, showed synergistic anti-tumor effect with chemotherapy including docetaxel, paclitaxel, and platinum in a pre-clinical trial of non-small cell lung cancer (22).